CHEMCO INNOVATIVE CHEMIE PRIVATE LIMITED

About CHEMCO INNOVATIVE CHEMIE PRIVATE LIMITED

Chemco International is an India-based specialty and fine chemical manufacturer focused on advanced intermediates, KSMs, and API-linked chemistry.

With over 35 years of manufacturing experience,we have built strong capabilities in nitration chemistry, process scale-up, and commercial manufacturing. Our portfolio includes pharma-linked intermediates for APIs and Nitration focused...

Certifications
  • Country/Region:
    India
  • Founded:
    1976
  • On CPHI since:
    2024
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
CMO/CDMO
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Chemical Development
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Intermediates Manufacturer
Contact info

Products from CHEMCO INNOVATIVE CHEMIE PRIVATE LIMITED (3)

  • 3-Acetamidophthalic Anhydride

    Product 3-Acetamidophthalic Anhydride

    Advanced Intermediate for Apremilast 
  • 2-Thiobarbituric Acid

    Product 2-Thiobarbituric Acid

    Color : White / Almost White / Light Yellow / Light Brown Form : Powder L O D (Loss on Drying) : Not more than 1% Sulphated Ash : Not more than 0.5% Foreign Matter : No Foreign Matter Assay by titration: Not less than 99% Packing : HDPE plastic drums with internal PE liners(25 Kg.Net each)
  • 5-Nitroisophthalic Acid

    Product 5-Nitroisophthalic Acid

    Color : Light Yellow / White or Almost White
    Form : Crystals or Crystalline Powder 

    Melting Point : Not less than 260-263°C
    Color of Solution : Less than GY5
    Loss on Drying (%) : Not more than 0.8 


    Assay by Titration: 99 - 101%





CHEMCO INNOVATIVE CHEMIE PRIVATE LIMITED Resources (2)

  • News Upcoming GMP Unit for Advanced Intermediates

    Chemco is expanding its pharmaceutical manufacturing capabilities through an upcoming GMP unit dedicated to advanced and penultimate intermediates. The facility is being developed to support customer programs linked to APIs including Acalabrutinib, Ambrisentan, Apixaban, Apremilast, Canagliflozin, Chlorthalidone, Dapagliflozin, Sotagliflozin, Doxofylline, Empagliflozin, Etoricoxib, Famotidine, Ibrutinib, Mirabegron, Tazemetostat, Ticagrelor and Praziquantel.

    The new unit will support process development, technology transfer, scale-up and commercial manufacturing, with a focus on reliable execution, long-term supply and customer-specific intermediate programs.